Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.0K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.0K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

1.9K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.9K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.5K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.5K
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

1.6K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unburdening healthcare systems through telenursing in chronic respiratory disease management: a systematic review.

Frontiers in digital health·2026
Same author

Impact of Single-Inhaler Triple Therapy FF/UMEC/VI on Disease Stability in COPD: A Real-World 12-Month Analysis.

Pulmonary therapy·2026
Same author

Sex-Based Comparison of Remission in Patients with Severe Type 2 Asthma Treated with Biologics: A Real-World Analysis from the "Southern Italy Network on Severe Asthma Therapy".

Respiration; international review of thoracic diseases·2026
Same author

Assessing response to biological therapies in severe asthma.

Expert review of clinical immunology·2026
Same author

Predictive Factors And Treatments Associated with Clinical Remission in Severe Eosinophilic Asthma.

Journal of inflammation research·2026
Same author

Effects of Tezepelumab in "United Airway Disease" (Asthma and CRSwNP).

Case reports in pulmonology·2026

Related Experiment Video

Updated: Apr 21, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K

COPD: maximization of bronchodilation.

Stefano Nardini1, Gianna Camiciottoli2, Salvatore Locicero3

  • 1Pulmonary and TB Unit, Vittorio Veneto General Hospital, Vittorio Veneto, TV Italy.

Multidisciplinary Respiratory Medicine
|November 4, 2014
PubMed
Summary
This summary is machine-generated.

Chronic Obstructive Pulmonary Disease (COPD) management requires evaluating more than airflow limitation. Combining long-acting bronchodilators (LABA/LAMA) improves symptoms and quality of life in severe COPD.

Keywords:
BronchodilationCOPDDyspneaExercise toleranceFixed combination indacaterol/glycopyrroniumHRQoLHyperinflationLABALAMA

More Related Videos

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.3K
Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
08:44

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Published on: February 2, 2024

1.5K

Related Experiment Videos

Last Updated: Apr 21, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

34.4K
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
09:58

A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice

Published on: April 13, 2010

22.3K
Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies
08:44

Author Spotlight: Integrating Alveolar-Capillary Reserve Measurements in Exercise Adaptation and Therapeutic Strategies

Published on: February 2, 2024

1.5K

Area of Science:

  • Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • COPD diagnosis traditionally relies on airflow limitation (FEV1/FVC ratio < 70%), but this doesn't fully correlate with symptoms or disability.
  • A multidimensional approach to COPD assessment is necessary, incorporating respiratory function, symptoms, exacerbation frequency/severity, functional status, and health-related quality of life (HRQoL).

Purpose of the Study:

  • To highlight the importance of a comprehensive COPD evaluation beyond spirometry.
  • To emphasize the role of bronchodilators, particularly long-acting inhaled beta-2 agonists (LABA) and antimuscarinic agents (LAMA), in managing stable COPD.
  • To discuss the benefits of combining LABA and LAMA for sustained bronchodilation and improved outcomes in severe COPD.

Main Methods:

  • Review of current COPD guidelines and therapeutic strategies.
  • Analysis of the mechanisms of action and clinical effectiveness of different bronchodilator classes.
  • Evaluation of treatment efficacy based on functional, symptomatic, and clinical endpoints.

Main Results:

  • Long-acting inhaled bronchodilators (LABA and LAMA) are recommended as baseline therapy for all COPD stages.
  • Combined LABA/LAMA therapy offers synergistic bronchodilation, optimizing outcomes in severe airflow limitation.
  • Fixed-dose combinations of ultra-LABA/LAMA provide sustained bronchodilation, potentially reducing bronchial caliber fluctuations.

Conclusions:

  • COPD management should integrate spirometry with symptom assessment, exacerbation history, and HRQoL.
  • Bronchodilators are crucial for improving exercise tolerance, reducing dyspnea, and enhancing HRQoL in COPD patients.
  • Combination therapy with LABA and LAMA is a valuable strategy for achieving maximal and sustained bronchodilation in severe COPD.